收费全文 | 26849篇 |
免费 | 1995篇 |
国内免费 | 92篇 |
耳鼻咽喉 | 465篇 |
儿科学 | 1045篇 |
妇产科学 | 391篇 |
基础医学 | 2664篇 |
口腔科学 | 564篇 |
临床医学 | 2312篇 |
内科学 | 6116篇 |
皮肤病学 | 596篇 |
神经病学 | 1559篇 |
特种医学 | 1198篇 |
外国民族医学 | 1篇 |
外科学 | 5143篇 |
综合类 | 400篇 |
一般理论 | 16篇 |
预防医学 | 1204篇 |
眼科学 | 973篇 |
药学 | 2309篇 |
中国医学 | 47篇 |
肿瘤学 | 1933篇 |
2023年 | 239篇 |
2022年 | 211篇 |
2021年 | 938篇 |
2020年 | 518篇 |
2019年 | 929篇 |
2018年 | 1133篇 |
2017年 | 718篇 |
2016年 | 757篇 |
2015年 | 783篇 |
2014年 | 1206篇 |
2013年 | 1450篇 |
2012年 | 2120篇 |
2011年 | 2083篇 |
2010年 | 1059篇 |
2009年 | 961篇 |
2008年 | 1511篇 |
2007年 | 1482篇 |
2006年 | 1381篇 |
2005年 | 1179篇 |
2004年 | 1047篇 |
2003年 | 880篇 |
2002年 | 758篇 |
2001年 | 599篇 |
2000年 | 567篇 |
1999年 | 493篇 |
1998年 | 162篇 |
1997年 | 128篇 |
1996年 | 135篇 |
1995年 | 154篇 |
1994年 | 115篇 |
1993年 | 100篇 |
1992年 | 270篇 |
1991年 | 287篇 |
1990年 | 250篇 |
1989年 | 214篇 |
1988年 | 209篇 |
1987年 | 219篇 |
1986年 | 192篇 |
1985年 | 177篇 |
1984年 | 111篇 |
1983年 | 125篇 |
1982年 | 85篇 |
1981年 | 71篇 |
1979年 | 129篇 |
1978年 | 77篇 |
1977年 | 68篇 |
1975年 | 58篇 |
1974年 | 65篇 |
1973年 | 88篇 |
1970年 | 58篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献